Format

Send to

Choose Destination
Chest. 2004 Mar;125(3):1028-32.

Pneumothorax in pulmonary Langerhans cell histiocytosis.

Author information

1
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Abstract

BACKGROUND:

Pulmonary Langerhans cell histiocytosis (PLCH) is a smoking-related interstitial lung disease characterized by development of cystic changes that predispose to occurrence of pneumothorax.

STUDY OBJECTIVES:

To determine the frequency, recurrence rate, and optimal management of pneumothorax associated with PLCH.

DESIGN:

Retrospective study.

SETTING:

Tertiary care, referral medical center.

PATIENTS:

One hundred two adults >or= 18 years old with histologically confirmed PLCH seen at Mayo Clinic Rochester over a 23-year period from 1976 to 1998.

INTERVENTIONS:

None.

MEASUREMENTS AND RESULTS:

Sixteen of 102 patients (16%) with PLCH had pneumothorax; mean age at the time of diagnosis was 29.4 years (range, 18 to 52 years), and all had smoked cigarettes. There were 37 episodes of pneumothoraces (1 to 5 episodes per patient); 10 patients (63%) had more than one episode. Median age at diagnosis of PLCH was significantly younger in patients with pneumothorax when compared to those without pneumothorax (27 years vs 41.5 years, p < 0.001), but pulmonary function parameters and survival after diagnosis were not significantly different. Rate of recurrent pneumothorax was 58% to the ipsilateral side when the episode was managed by observation or chest tube without pleurodesis, and 0% after surgical management with pleurodesis.

CONCLUSIONS:

These data support the early use of surgical therapy with pleurodesis in managing patients with PLCH and spontaneous pneumothorax.

PMID:
15006964
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center